225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
Latest Information Update: 27 Jan 2025
Price :
$35 *
At a glance
- Drugs Actinium-225-satoreotide-Ariceum-Therapeutics (Primary)
- Indications Merkel cell carcinoma; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SANTANA-225
- 27 Jan 2025 New trial record
- 14 Jan 2025 According to an Ariceum Therapeutics media release, the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial ('SANTANA-225') of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). Ariceum is working with its partners and clinical sites in the US and other countries to commence recruitment of patients in Q1 2025.